Key Takeaways Iovance's Amtagvi sales jumped 183% in the first nine months of 2025, driving growth.IOVA cut its 2025 revenue guidance and withdrew its EU filing for Amtagvi, hurting shares.Rigel's 2025 sales rose 60% to $232M, led by Tavalisse, with 2026 growth projected.Both Iovance Biotherapeutics (IOVA) and Rigel Pharmaceuticals (RIGL) are small-cap companies focused on the successful commercialization of their marketed products.While Iovance is a cancer biotech concentrated on developing immunotherapies ...

Core Insights - Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is recognized as one of the best-performing affordable stocks under $40, with preliminary results indicating strong revenue growth for Q4 2025 and an optimistic outlook for 2026 [1] Financial Performance - The preliminary revenue for Q4 2025 is projected to be approximately $69.8 million, an increase from $57.6 million in Q4 2024 [2] - Management anticipates gross product sales for Q4 2025 to reach $84.5 million, driven by TAVALISSE net product sales of $45.6 million, GAVRETO net product sales of $10.2 million, and REZLIDHIA net product sales of $9.6 million [2] - For the full year 2025, Rigel expects to achieve around $294.3 million in revenue, up from $179.3 million in 2024, with a projected total revenue for 2026 in the range of $275 million to $290 million [3] Market Sentiment - Following the preliminary results, Wall Street shows a bullish sentiment towards Rigel Pharmaceuticals, with Joseph Pantginis from H.C. Wainwright reiterating a Buy rating and setting a price target of $57 [3] Company Overview - Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on discovering and developing targeted, novel drugs in oncology, immunology, and immune oncology, with a product portfolio that includes Tavalisse, Fostamatinib, and R835 [4]

Company Overview - Profound Medical (PROF) shares increased by 9.5% to close at $8.34, with trading volume significantly higher than usual, contrasting with a 0.3% loss over the past four weeks [1] - The rise in share price followed the successful treatment of a prostate cancer patient at Mount Sinai Hospital using the TULSA-PRO system, which integrates advanced technologies for treatment [2] Financial Performance - The company is projected to report a quarterly loss of $0.28 per share, reflecting a year-over-year decline of 40%, while revenues are expected to reach $8 million, marking a 91.4% increase from the previous year [3] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Profound Medical operates within the Zacks Medical - Drugs industry, where Rigel Pharmaceuticals (RIGL) also holds a Zacks Rank of 3 (Hold) and has seen a 3.4% decrease in its share price [4][5] - Rigel's consensus EPS estimate for its upcoming report is $1.17, representing a 46.3% increase from the previous year, with its stock also experiencing a decline of 6.7% over the past month [5]

Core Insights - Centene Corporation (CNC) is enhancing its Medicaid-focused growth strategy through a new partnership with Cityblock Health, targeting 10,000 Medicaid members across 17 counties in Illinois [1][9] Partnership Details - The collaboration will provide a comprehensive 24/7 wrap-around care model, including primary and urgent care, behavioral health support, social care coordination, clinical pharmacy, and overall care management, specifically designed for Medicaid populations facing complex issues [2][9] - This partnership marks the fourth regional collaboration between Centene and Cityblock, following previous partnerships in New York, Ohio, and Florida, reflecting Centene's commitment to value-based care models [3][9] Strategic Implications - By integrating Cityblock's innovative care model, Centene aims to enhance member engagement, reduce unnecessary hospital visits, and lower overall care costs, which are crucial for maintaining healthy margins in Medicaid contracts [4][9] - Such partnerships may strengthen Centene's position as a leading Medicaid operator, adapting to evolving care models and enhancing its competitive edge with state regulators during contract renewals [5] Financial Performance - Over the past six months, Centene's shares have increased by 38.3%, significantly outperforming the industry growth of 10.7% [6]

Core Insights - Select Medical Holdings Corporation (SEM) has formed a joint venture with Vibra Healthcare to enhance inpatient rehabilitation services in Southern Kentucky, specifically operating the Southern Kentucky Rehabilitation Hospital in Bowling Green [1][9] Company Strategy - The 76-bed facility will focus on acute inpatient rehabilitation for patients recovering from serious conditions such as strokes, traumatic brain injuries, and spinal cord injuries, addressing critical needs in underserved markets [2][3] - This partnership is a strategic move for SEM to expand its post-acute care services in Kentucky, complementing its existing network of two critical illness recovery hospitals and 65 outpatient rehabilitation centers [3][4] - The collaboration aligns with SEM's long-term growth strategy of expanding its rehabilitation hospital portfolio through capital-efficient joint ventures, supporting its growth objectives in the post-acute care segment [4] Future Plans - SEM is planning to open three new inpatient rehab facilities in 2026, including locations in Tucson, AZ, Ozark, MO, and New Jersey, along with additional acute rehab and neuro transitional units [5] Financial Performance - In the first nine months of 2025, SEM's total revenues increased by 4.7% year over year, indicating positive growth despite a challenging market environment [4][9] - Over the past year, SEM shares have declined by 17.9%, which is an improvement compared to the industry's decline of 26.8% [6]

Industry Overview - The drug and biotech sector has shown recovery after a sluggish first half, supported by drug pricing agreements with the Trump administration and renewed M&A activity [1][4] - Innovation in areas such as obesity treatments, gene therapy, inflammation, and neuroscience continues to drive growth, despite challenges like pipeline setbacks and regulatory uncertainty [2][3] Market Performance - The Zacks Medical-Drugs industry has underperformed compared to the Zacks Medical sector and the S&P 500 over the past year, with a collective rise of 1.2% compared to 3.4% and 18.9% respectively [13] - The industry currently holds a Zacks Industry Rank of 90, placing it in the top 37% of 244 Zacks industries, indicating potential for outperformance [12] Valuation Metrics - The industry is trading at a trailing 12-month price-to-sales (P/S) ratio of 2.25, lower than the S&P 500's 6.03 and the Zacks Medical sector's 2.61 [16] Key Companies and Their Prospects - **Ironwood Pharmaceuticals**: Developing apraglutide for short bowel syndrome, with a significant rise in stock price by 178.9% in the past three months and a consensus estimate for 2026 earnings increasing from $0.40 to $0.47 [20][22] - **Rigel Pharmaceuticals**: Sales of Tavalisse rose by approximately 54% in the first nine months of 2025, with a stock increase of 46.7% and a consensus estimate for 2026 earnings rising from $3.70 to $4.30 [24][27] - **Soleno Therapeutics**: Launched Vykat XR for Prader-Willi syndrome, generating around $99 million in sales since April, with a stock decline of 25.7% but a rising consensus estimate for 2026 earnings from $3.10 to $3.59 [29][30] - **Marker Therapeutics**: Focused on next-generation T cell therapies, with a stock increase of 75.5% and a narrowing consensus estimate for 2026 loss per share from $4.92 to $1.86 [33][34] - **Nektar Therapeutics**: Developing rezpegaldesleukin for atopic dermatitis and alopecia areata, with a stock decline of 26.0% but a narrowing consensus estimate for 2026 loss per share from $12.17 to $10.81 [36][38]

Core Viewpoint - Rigel Pharmaceuticals, Inc. will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, highlighting its focus on hematologic disorders and cancer [1]. Company Overview - Rigel Pharmaceuticals, Inc. is a biotechnology company established in 1996, based in South San Francisco, California, dedicated to discovering and developing novel therapies for patients with hematologic disorders and cancer [3]. - The company is publicly traded on Nasdaq under the ticker symbol RIGL [3]. Event Details - The presentation will be led by Raul Rodriguez, the president and CEO of Rigel Pharmaceuticals, scheduled for 3:00 p.m. PT (6:00 p.m. ET) [1]. - Investors can access the live webcast or archived recording through the Investor Relations section of Rigel's website [2].

Core Insights - Rigel Pharmaceuticals announced updated data from its ongoing Phase 1b study of R289, an oral prodrug of R835, targeting relapsed or refractory lower-risk myelodysplastic syndrome (MDS) [1][2] - The study results were presented at the 67th American Society of Hematology Annual Meeting, highlighting the potential of R289 as a treatment option for patients with transfusion-dependent lower-risk MDS [1][2] Study Overview - The Phase 1b study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of R289 in patients with relapsed or refractory lower-risk MDS [2] - Enrollment in the dose escalation phase was completed in July 2025, with the dose expansion phase starting in October 2025, involving up to 40 patients [2] Key Data Highlights - As of October 28, 2025, 33 patients were enrolled, with a median age of 75 and a median of 3 prior therapies [4] - R289 was generally well tolerated, with 33% of evaluable transfusion-dependent patients achieving durable red blood cell transfusion independence (RBC-TI) [3][4] - The most common treatment-emergent adverse events included diarrhea (30%), constipation (27%), and fatigue (27%) [4] Efficacy Results - Among evaluable transfusion-dependent patients, 6 out of 18 (33%) achieved RBC-TI lasting more than 8 weeks, with a median time to onset of 1.9 months [4] - Peak hemoglobin increases ranged from 2.9 to 6.1 g/dL compared to baseline in patients achieving RBC-TI [4] Regulatory Designations - R289 has received Orphan Drug designation and Fast Track designation from the FDA for the treatment of previously-treated transfusion-dependent lower-risk MDS [5]

Core Insights - Rigel Pharmaceuticals has reported strong third-quarter earnings and raised its sales guidance, indicating positive momentum in its business performance [1][4] - The company's IBD SmartSelect Composite Rating has been upgraded from 94 to 96, placing it among the elite stocks with a rating above 95 [1][4] - Rigel Pharmaceuticals is nearing a buy point of a cup base, suggesting potential investment opportunities for traders [1] Financial Performance - Rigel Pharmaceuticals experienced a significant boost in its stock performance following the earnings report [1] - The company is part of the IBD 50 Growth Stocks To Watch, outperforming 94% of stocks tracked by Investor's Business Daily with a remarkable 152% increase [1] Market Position - The upgrade in Rigel's Composite Rating reflects its strong market position and investor confidence [4] - Other pharmaceutical stocks, such as Dianthus Therapeutics and PTC Therapeutics, have also seen improvements in their ratings, indicating a positive trend in the sector [4]

Core Insights - Rigel Pharmaceuticals, Inc. is a biotechnology company focused on hematologic disorders and cancer, and it will present an overview at the Jefferies Global Healthcare Conference on November 18, 2025 [1][3]. Company Overview - Rigel Pharmaceuticals, Inc. is dedicated to discovering, developing, and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer [3]. - The company was founded in 1996 and is based in South San Francisco, California [3]. Event Details - The presentation by Raul Rodriguez, the company's president and CEO, will take place at 10:00 a.m. GMT (5:00 a.m. ET) [1]. - Investors can access the live webcast or archived recording through the Investor Relations section of the company's website [2].